GILD.SW Gilead (SIX) +73.91% pre-market CHF114.78 25 Mar 2026: what to watch

Pre-market trading on 25 Mar 2026 shows GILD.SW stock jumped +73.91% to CHF114.78, the largest one-day move today on the SIX Switzerland board. This surge follows headlines linking Gilead Sciences, Inc. to a near-term deal and briefly pushed market cap to CHF142,490,187,600. Volume was light at 33 shares versus a 50-day average of 128,237, so traders should weigh news flow against liquidity before sizing positions.

Pre-market move and price details for GILD.SW stock

GILD.SW opened pre-market at CHF114.78, up CHF48.78 from the previous close of CHF66.00. The one-day percentage change reported was 73.91%. The intraday range recorded in the feed was CHF114.78 for low and high, reflecting the pre-market print and limited trade count.

News drivers behind the GILD.SW stock move

Market wires cited a potential acquisition that traders linked to the spike, which appears to be the main catalyst. Reuters reports Gilead agreed to buy a biotech firm in a deal reported above USD2.00 billion, a move that would expand oncology and rare-disease assets source.

GILD.SW stock fundamentals and valuation

Gilead Sciences, Inc. (GILD.SW) trades at PE 21.35 using EPS 5.38 and price CHF114.78, a reasonable multiple versus biotech peers. Free cash flow yield is about 4.09% and dividend yield is roughly 2.22%. The balance sheet shows net leverage with debt-to-equity near 1.27 and interest coverage of 10.21, supporting cash returns and M&A flexibility.

Technicals, liquidity and risk signals for GILD.SW stock

Technical indicators show an ATR of 1.45 and ADX at 100.00, signalling a strong directional move. Volume was 33 against an average of 128,237, so the price jump on low liquidity increases short-term volatility risk. Short-term traders should watch the Keltner channel upper band at 116.75 and the on-balance volume at -33.00 for follow-through.

Meyka AI grade and model forecast for GILD.SW stock

Meyka AI rates GILD.SW with a score out of 100: 71.09 / Grade B+ (BUY). This grade factors in S&P 500 and sector comparison, financial growth, key metrics and analyst signals. Meyka AI’s forecast model projects a 12-month base price target of CHF135.00, implying +17.62% vs the current CHF114.78; forecasts are model-based projections and not guarantees.

Analyst context, sector performance and what to watch

Independent company ratings on 18 Mar 2026 showed a B+ recommendation level and mixed metric scores. Healthcare sector average PE is about 29.73; Gilead’s relative PE of 21.35 keeps valuation attractive versus peers. Watch regulatory updates, formal deal documents, and product sales trends for Biktarvy and oncology launches as primary volume catalysts.

Final Thoughts

The pre-market surge in GILD.SW stock to CHF114.78 on 25 Mar 2026 is driven by deal-related headlines and confirmed by a sharp jump in price despite very low traded volume. Fundamental metrics show a PE of 21.35, EPS 5.38, dividend yield ~2.22%, and manageable interest coverage 10.21, which support medium-term valuation upside. Meyka AI’s model projects a 12-month target of CHF135.00, implying +17.62% from the current price; this forecast is model-based and not a guarantee. Traders should treat the move as news-sensitive: confirm deal details, monitor volume for validation, and compare any announced price to our forecast before adjusting positions. Meyka AI, our AI-powered market analysis platform, will update the forecast if material filings or earnings reports change the outlook.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.